The Morning Rise
Click here to share today's top cannabis news with a colleague.
Business, Public
Despite prospect of tax savings, MSOs express mix of hope, skepticism on rescheduling
The prospect of federal cannabis rescheduling is on everyone’s minds. Last week, two Chicago-based multistate operators, Green Thumb Industries (CSE: GTII) (OTCQX: GTBIF) and Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) addressed the issue in conjunction with their annual financial reports.
While GTI reported net income in 2023 of $36.3 million, Verano lost $113 million for 2023, a result it blamed primarily on “income taxes.” That ties directly into the topic of federal taxes and the 280E provision which bars marijuana companies from claiming standard business tax deductions.
The 280E provision would be nullified if the Drug Enforcement Administration were to embrace a rescheduling proposal, because 280E only applies to those dealing in Schedule I and II drugs. And that would mean immense tax savings for all cannabis-touching businesses.
During the company’s investor call, GTI CEO Ben Kovler said that rescheduling would be “helpful” for the company, “especially since we paid over $100 million in cash taxes for 2023.”  In addition, CFO Matt Faulkner estimated that rescheduling “should cut our tax burn in about half or so.”
For Verano’s part, CEO George Archos noted that if the company wasn’t subject to 280E, the company would have saved about $80 million “in federal and state tax dollars in 2023.”
Mixed outlook
But while Archos maintained an upbeat tone on the odds of cannabis rescheduling this year, GTI President Anthony Georgiadis said the company was “skeptical” that the Biden administration will complete the proposed cannabis rescheduling from Schedule I to Schedule III.
A formal announcement from the DEA has been hotly anticipated by observers for months following a recommendation by the U.S. Department of Health and Human Services last summer. But thus far the DEA has stayed mum on its cannabis policy plans.
“We remain skeptical on the timing of any fundamental federal reform, including rescheduling and capital market accessibility. As a reminder, we were left at the altar on SAFE Banking around this time last year,” Georgiadis said during GTI’s earnings call on Wednesday, referring to the shelving of the SAFE Banking Act in Congress after months of heated negotiations in 2022.
Archos, for his part, said “We continue to believe the DEA will agree with the HHS’s recommendation to reschedule cannabis from Schedule I to Schedule III. We expect the current administration will want to point to not only a promise, but an achievement.”
Additionally, Archos noted that state-level tax reform moves by lawmakers toward “decoupling cannabis” from 280E in Connecticut, Illinois, and New Jersey saved Verano about $16 million last year alone.
“Imagine the formidable cash flow potential we have if and when 280E is decoupled from all of our states and at the federal level,” Archos said.
But as with many things in the cannabis industry, uncertainty underscores all business activities.
“We continue to focus on building a business to succeed regardless of federal change, while remaining hopeful for the potential reclassification of cannabis to Schedule III,” Kovler said.
* * * *
Business, Public
Nextleaf Q1 sales climb to $4.1M, fueled by entrance into Alberta
Canadian cannabis processing company Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) reported a climb in revenue for the first quarter ending Dec. 31, 2023, driven by the company’s expansion into Alberta.
The company achieved a record $4.1 million in gross sales for the quarter, a 190% year-over-year increase and a 25.1% rise from the previous quarter.
Net revenue came out to $132,821 during the quarter versus a $559,013 net loss in the same period in 2022, according to regulatory filings. That’s still down sequentially from $387,640 in the previous quarter.
The rise in revenue is linked to the company’s expansion into Alberta and a broadened product range.
“I have a personal affinity towards Alberta and its success for us as a company, having spent over 20 years there,” interim CEO Emma Andrews said in a statement.
“This was my first full quarter as interim CEO, so I spent time visiting retailers in Alberta to support our company’s launch. It was gratifying to see first-hand how the products are gaining immediate traction and how the value proposition is resonating early on with retailers, particularly with our softgel SKUs.”
Nextleaf also outlined its plans for the upcoming quarter, including the launch of nine new products across Canada.
“The company substantially increased its distribution province-wide and achieved successful sell-through of all initial purchase orders, receiving reorders on all items within the quarter,” the firm said.
Overall, Nextleaf maintained its debt-free status while investing in inventory and manufacturing to support its sales expansion and commercialization initiatives.
That includes “equipment purchases to support manufacturing. The company also engaged new contract manufacturing partners to increase capacity and meet growing demand.”
Additionally, the company reported on recent equity and stock option activities, including the issuance of common shares to company executives and modifications to its stock option plan.
* * * *
March 13-14: Hall of Flowers, Ventura City, California
March 22: Green Market Report Cannabis Finance Summit, Boston (in partnership with NECANN)
March 22-23: New England Cannabis Conference (NECANN), Boston
April 9-11: MJ Unpacked, Atlantic City
May 16: Green Market Report Women’s Summit, New York City
Interested in being a speaker or a source for Green Market Report? Apply now!
Facebook Twitter Instagram YouTube RSS
Green Market Report © 2017 – 2024. All rights reserved.
Manage Preference     Subscribe     Advertise
View in Browser

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.